Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581839 · ClinicalTrials.gov registry record · Phase 2
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
A Phase 2 study of Metastatic Breast Cancer and Brain Metastases, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 2
- Study locations
NCT02581839 is a Phase 2 study of Metastatic Breast Cancer and Brain Metastases that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 9 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02581839, a Phase 2 study of Metastatic Breast Cancer and Brain Metastases, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 2
- Study locations
Study Summary
Subjects are asked to take part in a clinical research study that tests Eribulin, a new drug. Eribulin is an investigational (experimental) anti-cancer agent that has not been approved by the Food and Drug Administration (FDA) for use in patients with brain metastases. Eribulin is FDA approved for use in patients with metastatic breast cancer but the effect it may or may not have on brain metastases has not been studied.
Conditions Studied
Interventions
- DEVICE MRI
- DRUG Eribulin Mesylate
- DRUG Pre-Medication: Zofran
- DRUG Pre-Medication: Decadron
Study Locations (2)
Ohio
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-11-17 |
| Est. Completion | 2020-07-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02581839
The ClinicalTrials.gov registry entry for NCT02581839 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which MRI is the first listed.
NCT02581839 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02581839 about?
NCT02581839 is a clinical study titled "Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate". Subjects are asked to take part in a clinical research study that tests Eribulin, a new drug. Eribulin is an investigational (experimental) anti-cancer agent that has not been approved by the Food and Drug Administration (FDA) for use in patients with brain metastases. Eribulin is FDA approved for u...
What is the current status of trial NCT02581839?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2015-11-17. Estimated completion is 2020-07-02.
What conditions does trial NCT02581839 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Brain Metastases.
What interventions are being tested in trial NCT02581839?
The interventions under investigation include: MRI (DEVICE), Eribulin Mesylate (DRUG), Pre-Medication: Zofran (DRUG), Pre-Medication: Decadron (DRUG).
Who is sponsoring clinical trial NCT02581839?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02581839 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.